福森药业发布中期业绩 股东应占亏损2313.6万元 同比收窄37.37%

Core Viewpoint - Fosun Pharma (01652) reported a significant decline in revenue for the six months ending June 30, 2025, with earnings of 111 million RMB, representing a year-on-year decrease of 43.31% [1] Financial Performance - The company recorded a loss attributable to shareholders of 23.136 million RMB, which is a year-on-year reduction of 37.37% [1] - Basic loss per share was reported at 0.03 RMB [1]